Heather Howard-Rodriguez

Responsible for launching Azstarys, the First and Only methalphenadate prodrug for the treatment of ADHD in children, adolecents and adults. Worked extensively with pharmacies through stocking shortages.

• Launched Azstarys in a highly generic ADHD market.
• Provided product and disease state information in the ADHD market to Child/Adult Psychiatry, Child Neurology, and Pediatrics.
• Sold in a highly regulated C2 space.
• Member of the 2023 Market Access Team

Responsible for launching GOCOVRI as a First and Only FDA approved treatment for Levodopa Induced Dyskinesia in Parkinson's Patients. Built a market, educated physicians on patient types, access and distribution. Educated patients through advocacy and support group environment. Worked extensively in the specialty pharmacy distribution model. Identified and developed Dr. Paula Ravin out of UCLA as a GOCOVRI speaker.

• Finished 2019 Ranked #10 in the Nation
• Inaugural Advisory Board Member
• Q2 Prescriber Leader/ Q2 Treatment Form Leader
• Q3 Prescriber Leader
• Worked The Parkinson's Study Group and AAN
• Rotational Sales Trainer

Part of a beta test salesforce of eleven Psychiatry Sales Specialists nation wide, responsible for launching Nuplazid, the only FDA approved treatment for hallucinations and delusions associated with PD Psychosis in Psychiatry.

• Worked with LTC and Neurology overlaps to drive business
• Successful in organizing and routing a large territory
• Worked with in a hub specialty pharmacy system
• Worked with doctors and staff on how to navigate the specialty pharmacy arena

Responsible for the promotion of Nuvigil for narcolepsy and shift work disorder as well as Azilect for Parkinson's Disease. Also responsible for the promotion of Amrix to Pain Care Specialist including high volume Internal Medicine physicians. Launched Zecuity, a transdermal device for the treatment of migraines in Neurology.

• 2015: Attainment Nuvigil 101.5%, Azilect 109.1%, Amrix 102.1
• 2015: Launched Zecuity transdermal device, a Iontophoretic migraine treatment
• 2014: Area Region of the Year
• 2014: Azilect Dominator Award
• 2014: Attainment Nuvigil 104.4%, Azilect 100.4%, Amrix 107.6%
• Responsible for the treatment of Parkinson's disease promoting MAOB inhibitor Azilect
• 2013: Amrix Ace Award
• 2013: Attainment Nuvigil 113.7%, Amrix 118.6%
• 2012: Area Region of the Year
• 2012: Attainment Nuvigil 128.3%, Amrix 111.4%
• 2012: Re-Launches Amrix

Responsible for launching and promoting Nuvigil for narcolepsy and shift work disorder in Psychiatry and Neurology. Previously promoted Provigil, the First in class non-stimulant, wakefulness promoting agent. Launched and promoted Amrix in Pain Management and Rheumatology.

• 2011: Attainment Nuvigil 101%
• 2010: Attainment Nuvigil 104%
• Area Field Trainer for the launch of Nuvigil, traveled to train and certify representatives in the field
• 2008: Launched Amrix
• 2007: Attainment Provigil 100.2%
• 2006: Attainment Provigil 102.6%

Promoted Coreg for CHF and Avandia for Type 2 diabetes. Launched Levitra for Erectile Dysfunction and Paxil CR for Depression. Targeted physicians were Cardiologist, Endocrinologist, Urologists, Psychiatrists and Internal Medicine physicians. The territory comprised of Burbank, Glendale south to Hollywood.

• 2004: Ruby Tier Award Winner. Top 20% of sales force
• 2004: Coreg attainment at 129%. Avandia attainment 106%
• 2003: Launched Levitra exceeding goal at 135%
• 2003: Paxil CR attainment 162%
• 2002: Paxil attainment 133% before launching Paxil CR
• 2001: Avandia attainment 118%. Paxil attainment 208%